Clik here to view.
Guardant Health’s Shield™ Blood Test Approved by FDA as a Primary Screening...
PALO ALTO, Calif. Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the U.S. Food and Drug Administration (FDA) has approved the company’s Shield™ blood test...
View ArticleClik here to view.
Myrobalan Therapeutics 任命 Grant Bogle 为董事会成员
马萨诸塞州，梅德福 (美国商业资讯)– Myrobalan Therapeutics 是⼀家开发新型⼝服⼩分⼦治疗药物的⽣物技术公司，致⼒于在具有重⼤未满⾜临床需求的中枢神 经系统（CNS）疾病中修复神经损伤并恢复脑功能。该公司宣布任命Grant C....
View ArticleClik here to view.
Dr. Reddy’s Receives Positive CHMP Opinion From European Medicines Agency for...
HYDERABAD, India Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as “Dr. Reddy’s”), today announced that the...
View ArticleClik here to view.
LTZ Therapeutics Announces Over $20 Million Series A Financing for...
REDWOOD CITY, Calif. & SHENZHEN, China LTZ Therapeutics, an immunotherapy-focused biotech company, today announced the completion of the company’s Series A financing of over $20 million, to...
View ArticleClik here to view.
British Journal of Cancer: Zurletrectinib is a next-generation TRK inhibitor...
BEIJING InnoCare announced British Journal of Cancer, part of leading science journal Nature, recently published a paper entitled “Zurletrectinib is a next-generation TRK inhibitor with strong...
View ArticleClik here to view.
Guardant Health的Shield™血液检查被FDA批准为初级筛查选项，为医疗保险报销扫清了障碍，开创了结直肠癌筛查的新纪元
加州帕洛阿尔托 (美国商业资讯)– 领先的精准肿瘤学公司Guardant Health, Inc. (Nasdaq:...
View ArticleClik here to view.
Biocytogen Announces Option and License Agreement with IDEAYA Biosciences for...
BEIJING, China & SOUTH SAN FRANCISCO, Calif. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotech company focusing on the discovery of novel antibody/ADC...
View ArticleClik here to view.
百奥赛图宣布与IDEAYA Biosciences就具有同类首创潜力的B7H3/PTK7拓扑异构酶抑制剂有效载荷双特异性ADC项目达成选择权和许可协议
中国北京和加利福尼亚南旧金山 (美国商业资讯)– 百奥赛图（北京）医药科技股份有限公司（百奥赛图，股票代码：02315.HK），一家专注于新型抗体/ADC疗法开发的国际性生物技术公司，宣布与IDEAYA Biosciences, Inc. (Nasdaq: IDYA)，一家致力于发现和开发靶向治疗药物的肿瘤精准医疗公司，就有潜力的同类首创B7H3/PTK7...
View ArticleClik here to view.
In-Depth Report on Global Oesophageal Cancer Clinical Trials Now Available
SAN FRANCISCO Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics at...
View ArticleClik here to view.
IMS Shin-Matsudo Central General Hospital Completes First Patient Treatment...
SHINMATSUDO, Japan ZAP Surgical Systems, Inc., a leading innovator in the field of surgical robotics, today announced that IMS Shin-Matsudo Central General Hospital, located in the heart of...
View ArticleClik here to view.
诺为泰关于全球食管癌临床试验的深度报告现已发布
加利福尼亚州旧金山 (美国商业资讯)– Novotech（诺为泰）是一家专门与生物技术公司合作、加快各个阶段先进新型疗法的开发、可提供全方位服务的国际性临床合同研究组织 (CRO)。现在诺为泰发布了一份新的行业报告，题为《食管癌——全球临床试验概况》。 本新闻稿包含多媒体。此处查看新闻稿全文：...
View ArticleClik here to view.
The World’s First Initiative! Cluster, Inc. Collaborates with Okayama...
TOKYO Cluster, Inc, the largest metaverse platform in Japan with over 35 million event participants, collaborated with Associate Professor Hasei of the Department of Medical Information and...
View ArticleClik here to view.
Boston Oncology和King Fahd Medical City（KFMC）合作在沙特阿拉伯推进本地化细胞与基因疗法
马萨诸塞州坎布里奇和沙特阿拉伯利雅得 (美国商业资讯)– 根据旨在实现沙特阿拉伯王国医疗保健转型的重要倡议，Boston Oncology和King Fahd Medical City (KFMC) 签署了就细胞和基因疗法开展本地化合作的意向书。 本新闻稿包含多媒体。此处查看新闻稿全文：...
View ArticleClik here to view.
Takeda公布2024财年第一季度业绩——成长型产品和新产品表现强劲；前景看好的后期研发管线取得进展
日本大阪 (美国商业资讯)– Takeda (TOKYO:4502/NYSE:TAK)今日公布了截至2024年6月30日的2024财年第一季度财报，其成长型产品和新产品保持了稳定发展势头，使其核心业务在固定汇率基础上实现了增长，足以抵消上一财年大量的专利到期对营收造成的影响。...
View ArticleClik here to view.
バイオサイトジェン、IDEAYAバイオサイエンシズと将来の画期的新薬として期待される「B7H3/PTK7 トポイソメラーゼⅠ ペイロード...
中国、北京&カリフォルニア州、サウス・サンフランシスコ （ビジネスワイヤ） — 新規ADC治療薬の発見と開発に注力する世界的なバイオ・テクノロジー企業であるバイオサイトジェン製薬（北京）株式会社（以下「バイオサイトジェン」、HKEX：02315）は、IDEAYAバイオサイエンシズ（Nasdaq：IDYA）と、将来の画期的新薬として期待されている「B7H3/PTK7...
View ArticleClik here to view.
ボストン・オンコロジーとキング・ファハド・メディカル・シティ（KFMC）が、サウジアラビアにおける細胞・遺伝子治療のローカライズ推進で提携
米マサチューセッツ州ケンブリッジ＆サウジアラビア・リヤド （ビジネスワイヤ） — サウジアラビア王国の医療を大きく変える画期的な取り組みとして、ボストン・オンコロジーとキング・ファハド・メディカル・シティ（KFMC）は、細胞・遺伝子治療のローカライズ（現地化）について提携するために基本合意書に調印しました。...
View ArticleClik here to view.
BostonGene Announces Partnership with Takeda to Evaluate Immunotherapies...
WALTHAM, Mass. BostonGene, a leading provider of artificial intelligence (AI)-driven molecular and immune profiling solutions, announced that it will collaborate with Takeda on immuno-oncology...
View ArticleClik here to view.
BostonGeneは、AIを活用した分子プロファイリングによる免疫療法評価でTakedaとのパートナーシップを発表
WALTHAM, Mass. （ビジネスワイヤ） —...
View ArticleClik here to view.
Daiichi Sankyo and Merck Enter into Global Development and Commercialization...
BASKING RIDGE, N.J. & RAHWAY, N.J. Daiichi Sankyo (TSE: 4568) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, have expanded their existing global co-development and...
View ArticleClik here to view.
Zai Lab Announces Second Quarter 2024 Financial Results and Recent Corporate...
SHANGHAI & CAMBRIDGE, Mass. Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the second quarter of 2024, along with recent product highlights and corporate...
View Article